Single-dose vaccination of a recombinant parainfluenza virus 5 expressing np from h5n1 virus provides broad immunity against influenza a viruses

Journal of Virology

Volumn 87, Issue 10, 2013, Pages 5985-5993

  Li, Zhuo ^a   Gabbard, Jon D ^a   Mooney, Alaina ^a   Gao, Xiudan ^a   Chen, Zhenhai ^a   Place, Ryan J ^a   Mark Tompkins, S ^a   He, Biao ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAINFLUENZA VACCINE; VIRUS NUCLEOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA VIRUS; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA A (H5N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; VIROGENESIS; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PARAMYXOVIRIDAE; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL CORE PROTEINS;

EID: 84877344264     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00120-13     Document Type: Article

References (39)

1. Wright PFW. 2001. Orthomyxoviruses, p 1533-1579. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, Rimmelzwaan GF, Olsen B, Osterhaus AD. 2005. Characterization of a novel influenzaAvirus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79:2814 -2822.
3. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu X, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE, Donis RO. 2012. A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. U. S. A. 109:4269-4274.
4. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. 2005. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWRRecommend. Rep. 54(RR8):1-40.
5. Weekly Epidemiological Record. 2003. Influenza fact sheet. Wkly. Epidemiol. Rec. 78:77- 80.
6. Lipatov AS, Govorkova EA, Webby RJ, Ozaki H, Peiris M, Guan Y, Poon L, Webster RG. 2004. Influenza: emergence and control. J. Virol. 78:8951- 8959.
7. Epstein SL. 2003. Control of influenza virus infection by immunity to conserved viral features. Expert Rev. Anti Infect. Ther. 1:627- 638.
8. Portela A, Digard P. 2002. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J. Gen. Virol. 83:723-734.
9. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Nabel GJ. 2005. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23:5404 -5410.
10. Soboleski MR, Gabbard JD, Price GE, Misplon JA, Lo CY, Perez DR, Ye J, Tompkins SM, Epstein SL. 2011. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One 6:e21937. doi:10.1371/journal.pone.0021937.
11. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, Pearce MB, Pappas C, Tumpey TM, Epstein SL. 2010. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 5:e13162. doi:10.1371/journal.pone.0013162.
12. Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, Lambe T, Milicic A, Price DA, Hill AV, Gilbert SC. 2012. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One 7:e48322. doi: 10.1371/journal.pone.0048322.
13. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC. 2011. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 52:1-7.
14. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC. 2012. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis. 55:19 -25.
15. Chen Z, Yoshikawa T, Kadowaki S, Hagiwara Y, Matsuo K, Asanuma H, Aizawa C, Kurata T, Tamura S. 1999. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J. Gen. Virol. 80(Part 10):2559 -2564.
16. Robinson HL, Boyle CA, Feltquate DM, Morin MJ, Santoro JC, Webster RG. 1997.DNAimmunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J. Infect. Dis. 176(Suppl 1):S50 -S55.
17. Robinson HL, Hunt LA, Webster RG. 1993. Protection against a lethal influenza virus challenge by immunization with a haemagglutininexpressing plasmid DNA. Vaccine 11:957-960.
18. Ross TM, Xu Y, Bright RA, Robinson HL. 2000. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1:127-131.
19. Lamb RA, Kolakofsky D. 2001. Paramyxoviridae: the viruses and their replication, p 1487-1531. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
20. Azetaka M, Konishi S. 1988. Kennel cough complex: confirmation and analysis of the outbreak in Japan. Nippon Juigaku Zasshi 50:851- 858.
21. Binn LN, Eddy GA, Lazar EC, Helms J, Murnane T. 1967. Viruses recovered from laboratory dogs with respiratory disease. Proc. Soc. Exp. Biol. Med. 126:140 -145.
22. Cornwell HJ, McCandlish IA, Thompson H, Laird HM, Wright NG. 1976. Isolation of parainfluenza virus SV5 from dogs with respiratory disease. Vet. Rec. 98:301-302.
23. McCandlish IA, Thompson H, Cornwell HJ, Wright NG. 1978. A study of dogs with kennel cough. Vet. Rec. 102:293-301.
24. Rosenberg FJ, Lief FS, Todd JD, Reif JS. 1971. Studies of canine respiratory viruses. I. Experimental infection of dogs with an SV5-like canine parainfluenza agent. Am. J. Epidemiol. 94:147-165.
25. Chladek DW, Williams JM, Gerber DL, Harris LL, Murdock FM. 1981. Canine parainfluenza-Bordetella bronchiseptica vaccine immunogenicity. Am. J. Vet. Res. 42:266 -270.
26. Kontor EJ, Wegrzyn RJ, Goodnow RA. 1981. Canine infectious tracheobronchitis: effects of an intranasal live canine parainfluenza-Bordetella bronchiseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough). Am. J. Vet. Res. 42:1694 -1698.
27. He B, Paterson RG, Ward CD, Lamb RA. 1997. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 237: 249-260.
28. Chen Z, Xu P, Salyards GW, Harvey SB, Rada B, Fu ZF, He B. 2012. Evaluating a parainfluenza virus 5-based vaccine in a host with preexisting immunity against parainfluenza virus 5. PLoS One 7:e50144. doi: 10.1371/journal.pone.0050144.
29. Chen Z, Zhou M, Gao X, Zhang G, Ren G, Gnanadurai CW, Fu ZF, He B. 2013. A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein. J. Virol. 87:2986 -2993.
30. Li Z, Mooney AJ, Gabbard JD, Gao X, Xu P, Place RJ, Hogan RJ, Tompkins SM, He B. 2013. Recombinant parainfluenza virus 5 expressing hemagglutinin of influenzaAvirusH5N1protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge. J. Virol. 87:354-362.
31. Mooney AJ, Li Z, Gabbard JD, He B, Tompkins SM. 2013. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice. J. Virol. 87:363-371.
32. Tompkins SM, Lin Y, Leser GP, Kramer KA, Haas DL, Howerth EW, Xu J, Kennett MJ, Durbin RK, Durbin JE, Tripp R, Lamb RA, He B. 2007. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology 362:139 -150.
33. Baez M, Palese P, Kilbourne ED. 1980. Gene composition of highyielding influenza vaccine strains obtained by recombination. J. Infect. Dis. 141:362-365.
34. Sun D, Luthra P, Xu P, Yoon H, He B. 2011. Identification of aphosphorylation site within the P protein important for mRNA transcription and growth of parainfluenza virus 5. J. Virol. 85:8376-8385.
35. Sekaly RP. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205: 7-12.
36. Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR. 1994. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J. Virol. 68:3505-3511.
37. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. 2008. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 181:4168-4176.
38. Rangel-Moreno J, Carragher DM, Misra RS, Kusser K, Hartson L, Moquin A, Lund FE, Randall TD. 2008. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J. Immunol. 180:454-463.
39. Parks GD, Ward KR, Rassa JC. 2001. Increased readthrough transcription across the simian virus 5 M-F gene junction leads to growth defects and a global inhibition of viral mRNA synthesis. J. Virol. 75:2213-2223.